Novo Nordisk, the prominent Danish pharmaceutical company, has announced a significant rebranding initiative, adopting the name ‘Novo’ and implementing substantial changes to its corporate culture. This strategic move comes as the company intensifies its efforts to regain a competitive edge in the lucrative obesity drug market, facing mounting pressure from rivals and investors. The rebranding […]